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The mismatch-repair protein hMSH2 binds selectively to DNA 
adducts of the anticancer drug cisplatin 
Jill A Mello’, Samir Acharya2, Richard Fishe12* and John M Essigmann’* 
Bawround: The antitumor drug cis-diamminedichloroplatinum(ll) (cis-DDP or 
cisplatin) exerts its cytotoxic effects through the formation of covalent DNA 
adducts. A family of proteins possessing a common HMG box motif that binds 
specifically to cisplatin DNA adducts has been previously suggested to be 
important in the clinical efficacy of the drug. 
Results: We have shown that the human mismatch-repair protein, hMSH2, also 
binds specifically to DNA containing cisplatin adducts and displays selectivity for 
the DNA adducts of therapeutically active platinum complexes. Moreover, 
hMSH2 is overexpressed in testicular and ovarian tissue; tumors in these tissues 
are most effectively treated by cisplatin. 
Conclusions: Our results suggest a role for hMSH2 in mediating cisplatin 
toxicity. Supporting this view, previous studies in fscherichia co/i dam- strains 
demonstrate that mutations in mismatch-repair proteins confer resistance to 
cisplatin toxicity. Mismatch-repair deficiency is also correlated with tolerance to 
06-methylguanine, a cytotoxic DNA lesion formed by methylating agents. A 
current model ascribes 06-methylguanine toxicity to unsuccessful attempts at 
repair of this lesion by mismatch-repair proteins, resulting in a futile cycle of 
incision and synthesis, leading ultimately to lethal DNA-strand breaks. We 
propose that mismatch repair may contribute to cisplatin toxicity by a similar 
mechanism. Alternatively, hMSH2 may shield cisplatin adducts from repair, 
allowing adducts to persist, thus enhancing lethality. 
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Introduction 
The spectacular success of cisplatin (cis-diamminedichloro- 
platinum(I1) or cis-DDP; Fig. 1) in the treatment of 
testicular cancer and the impressive activity of the drug in 
delaying the development of ovarian and other cancers [l] 
has stimulated interest in its biochemical mechanism(s) of 
action. It is well established that cisplatin kills cells through 
processes triggered by its reaction with DNA [Z]. 
Cisplatin-DNA lesions formed by such reactions include 
intrastrand 1,2-d(GpG), 1,2-d(ApG), 1,3-d(GpNpG) (where 
N is any nucleotide), and interstrand crosslinks [3,4]. These 
DNA lesions are proposed to mediate cell death by 
inhibiting DNA and RNA synthesis [Z] and ultimately 
inducing apoptosis [S]. To date, however, the precise 
biochemical mechanism underlying the therapeutic activity 
and organotropism of cisplatin remains elusive and is likely 
to be more complex than the simple inhibition of 
polymerases in rapidly proliferating tumor cells. 
Of possible importance to the cytotoxic mechanism of 
cisplatin is the observation that various cellular proteins 
bind to cisplatin-DNA adducts [6]. Recently, a family of 
cisplatin-adduct binding proteins possessing a common 
high mobility group (HMG) box motif has been identified 
[7-91. Significantly, these HMG box proteins display a 
selective affinity for the DNA adducts of therapeutically 
active platinum compounds [&lo], suggesting a role for 
such proteins in potentiating cisplatin cytotoxicity. The 
HMG box domain is known to recognize bent DNA 
structures, such as four-way junctions and cruciform DNA 
[ 1 l-131. It is thus believed that duplex DNA bending and 
unwinding induced by cisplatin adducts [14,15] provide a 
structural signal for HMG box protein recognition [7,16]. 
Several models to explain the possible involvement of 
HMG box proteins in the mechanism of action of cisplatin 
have been proposed. One model suggests that binding of 
these proteins to platinum adducts precludes access to the 
lesions by DNA repair enzymes. Indeed, evidence has 
been presented both in vitro and in viva in support of the 
view that HMG box proteins sensitize cells to cisplatin by 
shielding cisplatin adducts from repair [9,17,18]. A second 
model stems from the identification of human upstream 
binding factor (hUBF) as one of the HMG box proteins 
attracted to therapeutic platinum-DNA adducts. hUBF is 
an important regulator of ribosomal RNA synthesis, which 
is essential for proliferating cells. hUBF binds to a 
cisplatin adduct (apparent dissociation constant, Kdcapp), 
60 PM) and to its cognate rRNA promoter sequence 
W 4app) = 18 PM) with comparable affinities, leading to 
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The structures of cisplatin and cisplatin analogs. Cisplatin (cis-DDP) 
and [Pt(en)CI,l (en, ethylenediamine), both therapeutically active 
platinum complexes, have chloride ligands in the cis geometry. The 
frans isomer of cisplatin, trans-DDP, and [Pt(dien)CIlCI (dien, 
diethylenetriamine) are clinically ineffective cisplatin analogs. 
the proposal that cisplatin adducts may act as molecular 
decoys for the transcription factor in &JO. Thus, by a 
‘transcription factor hijacking’ mechanism, cisplatin may 
deplete cells of a necessary resource for growth [ 191. 
To date the models advanced to explain the cytotoxicity 
of cisplatin have failed to explain an important feature of 
its pharmacological effects, namely its organotropic 
specificity for testicular and, to a lesser extent, ovarian 
tumors. We have recently reported that testicular tissue 
has elevated expression levels of the mRNA for the 
human mismatch repair protein, hMSH2 [ZO]. Mutations 
in the hMSH2 gene are a predisposing factor in the 
development of hereditary non-polyposis colorectal 
carcinomas [21,22]. A role for the Esc/terz&a co/i 
mismatch-repair proteins in sensitivity to the cytotoxic 
effects of cisplatin has been demonstrated by Marinus 
and coworkers [23]. Moreover, the observation that 
purified hMSHZ recognizes insertion/deletion mispairs 
as well as single-base mismatches [24,25] suggests that 
hMSH2 may recognize structural distortions in DNA. 
These observations, taken together, suggested to us that 
hMSH2 may interact with DNA that is damaged by 
cisplatin. Here, we demonstrate that purified hMSH2 
recognizes and binds specifically to DNA containing 
cisplatin adducts in vitro and, moreover, displays 
selective affinity for the DNA adducts of therapeutically 
active platinum compounds. These results suggest that 
mismatch repair may be involved in the sensitization of 
human cells to an important anticancer drug. 
Results 
hMSH2 binds to platinum-crosslinked DNA 
To test the hypothesis that hMSH2 might recognize 
cisplatin-modified DNA, purified hMSH2 was used in an 
electrophoretic mobility shift assay with DNA globally 
modified by cisplatin. Binding of hMSH2 to a radio- 
labeled 162-base pair (bp) DNA probe containing 
cisplatin-DNA adducts was readily observed by the 
retarded migration of the radiolabeled probe through the 
gel (Fig. 2, lane 4). Unlabeled nonspecific competitor 
DNA (chicken erythrocyte DNA of homogeneous length) 
was required in the binding reactions to observe discrete 
bands. Under identical conditions the protein did not 
cause a shift of unmodified 162-bp probe (Fig. 2, lane 2). 
A hallmark of the interaction of HMG box proteins with 
platinum-damaged DNA is the selectivity for adducts of 
therapeutically active platinum compounds [&lo]. To 
determine whether hMSH2 displays similar selectivity, 
Figure 2 
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Selectivity of hMSH2 for DNA modified with therapeutically active 
platinum compounds. A radiolabeled 162-bp DNA probe was modified 
with cisplatin (lanes 3 and 4), trans-DDP (lanes 5 and 6), [Pt(en)CI.J 
(EN, lanes 7 and 8), or [Pt(dien)CIlCI (DIEN, lanes 9 and 10) at drug- 
to-nucleotide ratios (rb) of 0.018, 0.036, 0.012, and 0.020, 
respectively. Unmodified 162-bp probe was used as a control (lanes 1 
and 2). DNA probes were incubated in the absence (-) or presence 
(+) of hMSH2 (100 nM). Cisplatin-modified probes migrate slower 
than unmodified DNA, as described previously [161. Two discrete, 
shifted bands were observed only when hMSH2 was incubated with 
DNA containing adducts of the therapeutically active complexes 
cisplatin or [Pt(en)CIsl (lanes 4 and 8, respectively). 
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we examined the interaction of hMSH2 with DNA 
modified by various cisplatin analogs (Fig. 1). hMSH2 
bound to DNA modified by the therapeutically active 
platinum analog [Pt(en)ClJ (Fig. 2, lane 8), although to a 
lesser extent than was observed for cisplatin-modified 
DNA. By contrast, hMSH2 had no affinity for DNA that 
contained adducts of the inactive platinum complexes 
trans-diamminedichloroplatinum(I1) (trans-DDP) and 
[Pt(dien)Cl]+ (Fig. 2, lanes 6 and 10, respectively). 
Cisplatin and [Pt(enQ] differ from the two clinically 
inactive compounds in that the chloride ligands have a cis 
geometry, enabling the formation of l,Z-intrastrand 
crosslinks at adjacent nucleotides. These crosslinks, 
formed at GG and AG sites, comprise greater than 90 % of 
all adducts formed by cisplatin [3,4]. Our binding results 
suggest that hMSH2 may recognize either or both of the 
1,2-intrastrand platinum adducts. Less binding was 
observed to DNA modified with [Pt(en)C12] compared to 
that with cisplatin. These two platinum complexes are 
believed to form the same spectrum of adduces [3]. This 
differential binding may be due in part to a slight 
difference in modification level of the two DNA probes 
(rb = 0.018 vs 0.012). These results may also indicate that 
substitution of the two amine groups of cisplatin with a 
bidentate ligand (ethylenediamine) negatively affects 
hMSH’Z-cisplatin adduct interactions. 
Specificity of hMSH2 binding to cisplatin DNA adducts 
To characterize the nature of the interaction between 
hMSH2 and cisplatin-modified DNA further, hMSH2 
protein was titrated into binding reactions containing a 
constant concentration of cisplatin-modified DNA probe. 
At hMSH2 concentrations approximating half-maximal 
binding, two distinct bands were consistently observed 
(Fig. 3a). The addition of increasing amounts of protein 
caused the complex to be proportionately retarded 
through the gel, presumably because multiple proteins 
bound to the multi-platinated probe. The binding iso- 
therm (Fig. 3b) reveals that the fraction of bound probe 
increases to saturation over a narrow range of hMSH2 
concentrations, consistent with positive cooperative 
hMSH2 binding (Hill constant, nH = 2.4). The 16Z-bp 
probe used in this experiment contained an average of six 
platinum adducts per duplex molecule (one platinum 
adduct per 27 bp). The apparently cooperative binding 
behavior may thus be a consequence of multiple platinum 
adducts situated in relatively close proximity in the 
duplex DNA; the binding of one hMSH2 molecule to a 
platinum adduct may render the subsequent binding of a 
second hMSH2 molecule to a nearby platinum adduct 
more favorable. Alternatively, hMSH2 may be binding as a 
dimer or some higher-ordered complex, as has been 
previously proposed [ZS]. Generation of the binding 
isotherm yielded a Kdcapp) = 67 nM. Neither the active 
fraction of our hMSH2 preparation nor the aggregation 
Figure 3 
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Binding isotherm describing the interaction between hMSH2 and 
cisplatin-modified DNA. (a) hMSH2 protein was titrated into binding 
reactions containing 124 pM of a radiolabeled 162-bp probe that 
contained an average of six cisplatin DNA adducts (rb = 0.018). 
Cisplatin-modified probe in the absence of hMSH2 is shown in lane 1. 
(b) The fraction of bound probe in each lane was quantitated by 
Phosphorlmager analysis and is presented as a function of the 
concentration of hMSH2 present in the binding reactions. The binding 
curve was generated by fitting these binding data to the Hill equation. 
state of the protein have been established, and thus our 
estimation of K,(,,,) assumes that hMSH2 binds as a 
monomer and that 100 % of the protein is active in 
cisplatin-adduct binding. These considerations, taken 
together with the observed complex nature of hMSH2 
binding to the multi-platinated probes, dictate that the 
K d(app) be considered only an approximation of the affinity 
of hMSH2 for a platinum adduct. 
The specificity of the interaction between hMSH2 and 
cisplatin-modified DNA was examined by an analysis of 
the competition between [32P]-platinated DNA and non- 
radioactive platinated or unmodified supercoiled plasmid 
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DNA for hMSH2 binding. Increasing concentrations of 
unlabeled competitor DNA, either modified with cisplatin 
(rb = 0.043) or unmodified control, were titrated into 
binding reactions containing hMSH2 and radiolabeled, 
platinated, 162-bp probe (rb = 0.018). A representative 
experiment is shown in Figure 4. A 400-fold molar excess 
of competitor platinum adducts was required to achieve 
complete competition of hMSH2 binding. An approxi- 
mately five-fold greater concentration of unmodified 
competitor DNA compared with cisplatin-modified DNA 
was required to reduce binding by 50 % (Fig. 4b). This 
differential affinity is comparable to that observed when 
examining the binding of the Saccharomyces cerevisiae 
MSHZ protein to a G-T mismatch, four-base loop, or 
1Cnucleotide palindromic insertion loop relative to homo- 
duplex DNA [26]. Previous studies of the interaction of 
hMSH2 with DNA probes containing one-base mis- 
matches or insertion/deletion loops also found similar 
selectivity over homoduplex DNA [24,25]. 
hMSH2 binds to DNA with low levels of cisplatin adducts 
The degree of DNA modification by cisplatin used in the 
above experiments, approximating one DNA adduct per 27 
Figure 4 
bp, is significantly higher than would be encountered in 
viuo. To examine whether hMSH2 binds to DNA 
containing levels of cisplatin modification more closely 
approximating those found in cellular DNA, binding assays 
were carried out with hMSH2 and 162-bp probes modified 
to a range of r,, levels. Discrete shifted bands that repres- 
ented specific binding to a cisplatin modified DNA probe 
of rr, = 0.018 (Figs 2,3,4 and Fig. 5, lane 8) were also 
observed when hMSH2 was included in binding reactions 
with DNA probes of rb = 0.010 (Fig. 5, lane 7), 0.0040 (lane 
6), 0.0025 (lane 5) and 0.0012 (lane 4). The fraction of probe 
bound diminished proportionately as the cisplatin modifi- 
cation level decreased, reinforcing the specific nature of 
this shifted band. The appearance of an increased fraction 
of unshifted material was probably a reflection of an 
increasing population of unmodified DNA. The lowest 
modification level, rb = 0.0012, corresponded to an average 
of 0.4 cisplatin adducts per probe molecule. The Poisson 
distribution predicts that 27 % of this DNA population 
would contain a single adduct, 6 % would have two 
adducts, and that the remainder of the population would be 
unmodified. These data thus suggest that hMSH2 can bind 
to DNA containing a single cisplatin adduct. 
(a) Platinated Unmodified 
competitor (PM) competitor (PM) 
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(b) 80 
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Specificity of hMSH2 binding to cisplatin- 
modified DNA. Unlabeled duplex DNA, either 
cisplatin-modified or unmodified control, was 
used to compete with a radiolabeled 162-bp 
cisplatin-modified DNA probe for association 
with hMSH2. (a) 32P-labeled 162-bp probe 
modified with cisplatin (rr, = 0.018, 150 PM) 
was incubated in the presence of hMSH2 
(100 nM) and O-71 0 pM unlabeled cisplatin- 
modified DNA (rr, = 0.043) (left panel), or 
O-6400 pM unlabeled unmodified DNA 
(right panel). Cisplatin-modified probe in the 
absence of hMSH2 is shown in lane 1 for 
either competitor. (b) The fraction of bound 
probe in each lane was quantitated by 
Phosphorlmager analysis and is presented as 
a function of the concentration of competitor 
DNA present in the binding reactions. 0, 
platinated DNA; n , unmodified DNA. 
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Figure 5 
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Binding of hMSH2 to cisplatin-modified DNA at different bound ratios 
of platinum to nucleotide. Radiolabeled 162-bp probe modified with 
cisplatin at drug-to-nucleotide ratios of 0.0012 (lane 4), 0.0025 (lane 
5) 0.0040 (lane 6) 0.010 (lane 3 and 7) and 0.018 (lane E), 
corresponding to an average of 0.4, 0.8, 1.3, 3.4 and 6 cisplatin 
adducts per probe molecule, respectively, were incubated in the 
absence (-) or presence (+) of hMSH2 (130 nM). Unmodified probe 
was used as a control (lanes 1 and 2). Retarded bands representing 
specific binding of hMSH2 to the DNA probe of rb = 0.018 (Figs 2, 3 
and 4 and Fig. 5, lane 8) were also present at the lower levels of 
platinum modification. Specific binding diminished as the degree of 
cisplatin modification decreased. The broad, faster-migrating band 
present in all lanes containing protein represents nonspecific binding 
to the 162sbp probe that was incompletely competed out by 
nonspecific competitor DNA present in the binding reactions. 
hMSH2 binds to the major cisplatin adduct 
The 1,2-intrastrand d(GpG) cisplatin crosslink represents 
65% of all adducts formed by this compound [Z]. The 
observation that hMSH2 binds to globally modified DNA 
in which a maximum of one to two cisplatin adducts were 
present suggested that hMSH2 may recognize this 
1,2-d(GpG) crosslink. The specificity of hMSH2 for 
platinum compounds that uniquely form 1,2-intrastrand 
crosslinks also supported this view. We therefore examined 
binding by hMSH2 to a lOO-bp probe containing a single 
d(GpG) adduct. Binding assays revealed a discrete band 
that was specific to the platinated probe (Fig. 6), 
demonstrating that hMSH2 recognizes the major cisplatin 
crosslink. Nonspecific binding to the lOO-bp probe was 
high in these gel-shift assays, precluding our ability to 
perform thermodynamic analysis of the interaction with 
confidence. The 1,2-d(GpG) adduct present in a shorter 
DNA probe and in a different sequence context may be 
useful in such studies. 
hMSH2 is overexpressed in human testicular and 
ovarian tissues 
The expression of hMSH2 was examined by Western 
analysis of protein extracts prepared from five different 
human tissues using an hMSHZ-specific monoclonal 
antibody. The same amount of total protein was analyzed 
for each tissue examined. A protein band of relative 
molecular mass (M,) 105 000 was observed in all five 
human tissues, corresponding to full length hMSH2 (Fig. 
7a). In addition, a lower band of - M, 75 000 that was of 
approximately equal intensity to the full length hMSH2 
band was observed in all tissues except the ovary, where 
the lower band was present but faint. This lower band was 
seen both when using a monoclonal antibody (Fig. 7) and 
when using a polyclonal antibody to hMSH2 (data not 
shown) and was not a nonspecific signal due to secondary 
antibody. This protein band is believed to be a specific 
degradation product of hMSH2 present in these tissue 
extracts. As a control, these same five human tissue 
extracts were analyzed by Western analysis for a-tubulin 
expression (Fig. 7b). A sharp band of M, 50 000 
corresponding to cx-tubulin was observed. Essentially 
similar levels of a-tubulin were found in all five protein 
extracts, demonstrating similar total protein content for 
each tissue extract. 
High levels of hMSH2 protein were found in both 
testicular and ovarian tissue, whereas lower levels were 
observed in tissue of the liver, heart, and colon. 
Quantitative analysis of hMSHZ-specific signals and 
normalization to that of a-tubulin for each tissue 
examined indicated that this enrichment of hMSH2 in 
testicular and ovarian tissue is approximately five-fold. 
The observed overexpression of hMSH2 protein in the 
Figure 6 
Control cis-DDP 
-+-+ 
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+- Nonspecific 
Binding of hMSH2 to a 1 00-bp probe containing a single, site-specific 
1,2-d(GpG) cisplatin intrastrand crosslink. hMSH2 (160 nM) was 
incubated with a 1 00-bp probe that contained the major cisplatin 
adduct or with its unplatinated control (100 PM). A discrete, shifted 
band was visible, which was specific for the platinated probe, while a 
faster migrating band, representing nonspecific binding, was observed 
with both the platinated and unplatinated probes. 
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Western blot analysis of hMSH2 expression 
in human tissue. (a) Protein extracts derived 
from human tissues were separated by 
electrophoresis on SDS-polyacrylamide gels, 
transferred to nitrocellulose, and probed with 
monoclonal antibody to hMSH2. Nuclear 
extract of HeLa cells and purified hMSH2 
were included as positive controls. Lane 1, 
heart; lane 2, liver; lane 3, ovary; lane 4, 
testis; lane 5, colon; lane 8, HeLa nuclear 
extract; lane 7, purified hMSH2 from a 
separate loading. The upper band 
corresponds to full length hMSH2 protein, M, 
105 000. The lower band is believed to be a 
specific degradation product of hMSH2 
present in these tissue extracts. (b) Protein 
extracts from human tissues were blotted and 
probed with monoclonal antibody to 
a-tubulin, demonstrating similar total protein 
content for each tissue sample. 
testis is consistent with previous results showing that 
hMSH2 is overexpressed in human testicular tissue at the 
RNA level [ZO]. However, elevated levels of hMSH2 
RNA were not previously found in ovarian tissues [ZO], 
suggesting that posttranscriptional regulatory mecha- 
nisms may be responsible for the elevated levels found in 
these tissues. Tumors that arise in tissues of the testis and 
ovary are those best treated by cisplatin [l]. The 
correlation of the enrichment of hMSH2 in these tissues 
with tumor response to cisplatin treatment suggests that 
the protein could be involved in sensitizing these tissues 
to cisplatin toxicity. 
Discussion 
We have shown that the human mismatch repair protein 
hMSH2 recognizes and binds specifically to duplex DNA 
containing cisplatin DNA adducts. hMSH2 also binds to 
DNA containing adducts of the clinically effective 
cisplatin analog [Pt(en)ClJ, but not to DNA modified 
with the therapeutically inactive platinum complexes 
trans-DDP or [Pt(dien)Cl]+. Binding specificity for DNA 
adducts of therapeutically active platinum complexes has 
previously been observed for a family of HMG box 
proteins. To date, however, no correlation between 
specific HMG proteins and the sensitivity of tissues to 
cisplatin has been found. Western analysis of hMSH2 
protein in the human tissues tested corroborates previous 
results showing that this protein is overexpressed in 
tissue of the testis and indicates for the first time that 
hMSH2 is also present at elevated levels in ovarian 
tissue. These observations are significant in that cancers 
occurring in testicular and ovarian tissues are those most 
successfully treated by cisplatin. These results suggest 
that mismatch-repair proteins could be involved in the 
antitumor activity and organotropism of cisplatin. 
The selective affinity of hMSH2 for DNA modified with 
cisplatin or [Pt(en)Clz], but not for DNA modified with 
other platinum complexes, suggested that this protein 
may recognize the 1,2-intrastrand crosslinks formed 
uniquely by these two compounds. Binding of hMSH2 to 
globally modified probes that contained a maximum of 
one to two cisplatin adducts further suggested that at least 
one of the 1,2-intrastrand crosslinks, which comprise 
-90 % of the total adduct spectrum of the drug, were 
recognized by hMSH2. Setting precedent for such 
specificity is HMGl, which binds selectively to cisplatin 
intrastrand 1,2-d(GpG) and 1,2-d(ApG) crosslinks, but 
lacks specificity for 1,3-d(GpNpG) crosslinks [8]. 
Although it has been shown that HMGl can bind to the 
interstrand crosslink of cisplatin, but not to that formed by 
trans-DDP [27], the infrequency with which the cisplatin 
interstrand adduct is formed (2 %) [Z] suggested that 
recognition of this adduct was less likely. Binding assays 
using a lOO-bp probe containing a single, site-specific 
1,2-d(GpG) crosslink (Fig. 6) demonstrated that this major 
adduct (65 %) is indeed recognized by hMSH2. This 
result does not exclude the possibility that the less 
abundant 1,2-d(ApG) crosslink may also be recognized. 
It is not yet clear how the structures of mispairs in the 
DNA helix affect recognition by hMSH2. It is possible, 
however, that cisplatin adducts distort DNA in a manner 
that mimics the presence of either a single-base mismatch 
or insertion/deletion mispair. Both S. cereeisiae and human 
MSHZ display greater selectivity for palindromic and loop 
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insertion mispairs compared to single-base mismatches 4n 
vitro [25,26]. HMG box proteins are known to bind DNA 
containing sharp angles, such as cruciforms and four-way 
junctions [l l-131. Of note is the resemblance between the 
cruciform DNA structures bound by HMG proteins and 
the palindromic insertion structures for which MSHZ 
proteins display greatest affinity [25,26]. Further studies 
probing the nature of the interaction of hMSH2 with 
cisplatin DNA adducts are clearly warranted. 
Although binding by hMSH2 to a single, site-specific 
1,2-d(GpG) cisplatin adduct was observed, high non- 
specific binding precluded thermodynamic analysis of this 
interaction. The apparent dissociation constant for the 
binding of hMSH2 to a DNA fragment containing multiple 
cisplatin adducts, however, was estimated to be 67 nM. It 
must be emphasized that due to the complex nature of 
binding to the multi-platinated probe in our experiments 
(see above), this Kdcapp) is only an approximation of the 
affinity of hMSH2 for a platinum adduct. To date, affinity 
constants have not been reported for mispair binding with 
either S. cerevisiae or human MSHZ. 
Competition studies demonstrated a five-fold greater 
affinity for DNA containing cisplatin adducts as compared 
to unmodified DNA. Previous mispair-binding studies with 
both the S. cerevisiae and human MSHZ proteins revealed a 
similar level of specificity for DNA containing one-base 
mismatches or insertion/deletion loops over homoduplex 
DNA [24-‘261. This relatively modest selectivity of MSHZ 
proteins for DNA mispairs in vitro seems at variance with 
their efficient repair in vivo. The recent discovery that 
hMSH2 can be purified as a complex with another human 
MutS homolog, GTBP/pl60 [Z&29], may provide a partial 
explanation for binding selectivity. The published evidence 
suggests that hMSH2 and GTBP/pl60 are required for the 
recognition of single- and one-base mispairs, but that 
hMSH2, either alone or in complex with an as yet 
unidentified protein, is capable of recognizing larger loops 
[29-311. In S. cerevisiae, Marsischky etal. [31] have recently 
shown that MSHZ forms a heterodimer not only with 
MSH6, the homolog of GTBP/pl60, but also with yet 
another MutS homolog, MSH3. Their results indicate that 
the MSHZ-MSH3 complex has a greater affinity for 
insertion/deletion loops than for single-base mispairs. 
Similar results have been found with the human homologs 
(S.A. et a/., unpublished data). Given that hMSH2 alone is 
capable of binding mispairs, it is possible that GTBP/pl60 
and the human homolog hMSH3 (DUG) serves to 
modulate binding specificity. Future studies will address 
the question of how these partner proteins affect the 
binding of hMSH2 to cisplatin adducts. 
The present results are the first demonstration that 
purified hMSH2 can bind to DNA lesions other than 
mispaired bases or loops. This binding of hMSH2 to 
cisplatin adducts could reflect the involvement of 
mismatch-repair proteins in the removal of cisplatin 
adducts from DNA. This possibility is underscored by the 
discovery of an association of the genes involved in 
mismatch correction with transcription-coupled nucleotide 
excision repair in both E. coli [32] and eukaryotes [33]. We 
note, however, that the selective affinity of hMSH2 for 
DNA adducts of clinically effective platinum complexes 
suggests an opposing role for hMSH2, that of mediating 
cisplatin toxicity. Interestingly, a connection between 
mismatch repair and cisplatin lethality has existed in the 
literature for some time. Early work by Marinus and 
coworkers [23,34] shows that dam- strains of E. coli, which 
have decreased adenine methylase activity and thus are 
unable to distinguish between parental and newly 
replicated DNA strands, are hypersensitive both to the 
methylating agent N-methyl-N’-nitro-N-nitrosoguanidine 
(MNNG) and to cisplatin. Significantly, the introduction of 
a mutation in either mats or mutL, which inactivates 
mismatch-repair activity in these cells, abrogates 
hypersensitivity to both agents [23,34,35]. E. co/i dam- and 
wild type strains are not differentially sensitive to the 
therapeutically inactive platinum compound tram-DDP. 
Connections between resistance to MNNG and defective 
mismatch repair have also been observed in higher 
eukaryotes. Goldmacher et al. [36] isolated an MNNG- 
resistant derivative of the human lymphoblastoid cell line 
TK6. This variant cell line exhibits a mutator phenotype, 
and extracts from this variant line have defective 
mismatch-repair activity in vitro [37]. The observed 
MNNG-resistant phenotype is not due to increased repair 
of 06-methylguanine (06-MeGua), but is instead an 
acquired ability to tolerate the presence of the methylated 
base in DNA [38]. Independent examples of methylation- 
tolerant cell lines that are defective in mismatch repair 
subsequently have been reported [39-41]. A model to 
explain this apparently paradoxical correlation of a defect 
in repair with the tolerance of methylation damage 
proposes a futile cycle of excision repair [34,36]. In this 
model, 06-MeGua lesions formed in DNA are presumed 
to be recognized by the mismatch-repair system due to 
the absence of a good complementary match for the 
methylated base. Repair attempts at 06-MeGua- 
containing base pairs would be directed at the newly 
synthesized strand after DNA replication; failure to find a 
correct base pair for 06-MeGua would invoke a futile 
cycle of incision and resynthesis in the opposing strand, 
resulting in the accumulation of lethal DNA strand 
breaks. Tolerance results when a defect in mismatch 
repair precludes initiation of this abortive repair. 
Supporting this hypothesis is the demonstration that a 
G-T mismatch-binding activity in cell extracts recognizes 
and binds to 06-MeGua-T base pairs in vitro [42]. 
Moreover, a study examining the processing of @-MeGua 
in plasmid DNA by human cell extracts demonstrates that 
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06-MeGua can be processed by a pathway involving 
excision and resynthesis of DNA that is not associated 
with the 06-MeGua-DNA methyltransferase enzyme [43]. 
Our present findings, viewed together with the original 
observations of Marinus, suggest that a mechanism 
analogous to that proposed for 06-MeGua could be 
operative in cellular processing of cisplatin adducts. By 
this model (summarized in Fig. 8) the mismatch-repair 
system, at least one component of which (hMSH2) is 
overly expressed in testis and ovary, recognizes cisplatin- 
modified bases in DNA. Binding by hMSH2 would trigger 
the recruitment of other mismatch-repair proteins and the 
consequent initiation of misdirected repair attempts at 
sites of cisplatin damage; abortive repair activity could 
provide, perhaps through the accumulation of DNA strand 
breaks, a signal for apoptosis. DNA strand breaks have 
been observed in cells after treatment with cisplatin, 
although it is unclear whether they originated from repair 
activity or as a consequence of apoptosis [44]. Based on 
current evidence, it is possible that recognition of cisplatin 
Figure 8 
adducts by hMSH2 in complexed form with partner 
proteins would be required for this model to be operative. 
Future studies examining whether these proteins, 
GTBP/p160 and hMSH3, modulate the affinity of 
hMSH2 for cisplatin adducts will be useful in assessing 
the feasibility of this model. 
A second and equally plausible mechanism by which 
hMSH2 could contribute to the therapeutic activity of 
cisplatin again derives from the abundance of this protein 
in ovarian and testicular tissue. Evidence exists supporting 
the view that HMG box proteins sensitize cells to cisplatin 
by shielding cisplatin adducts from repair [9,17,18]. To 
date, however, no correlation between the levels of HMG 
proteins and the sensitivity of target tissues to cisplatin has 
been found. The discovery that hMSH2, which lacks an 
HMG box, is able to bind cisplatin adducts and is also 
overexpressed in testicular and ovarian tissue suggests the 
possibility that it may form a complex with cisplatin 
adducts that is refractory to nucleotide excision repair. 
Slow repair would result in selective retention of the signal 
Cisplatin adduct 
hMSH2 
hMSH3 
GTBP/pl60 (hMSH6) 
Mismatch recognition 
protein(s) bind to 
cisplatin adduct 
G2 arrest 
followed by 
cell death 
Accumulation of 
strand breaks 
, Other mismatch I A I 
repair proteins 
recruited 
-’ 
hMLH1 1 
hPMS1 7 
Incision 
Abortive 
repair 
activity 
Nicked DNAC hMSH2 binding triggers 
apoptosis by unknown pathway 
The abortive repair model for the role of hMSH2 in potentiating induction of apoptosis, perhaps through the accumulation of DNA 
cisplatin cytotoxicity. In this model, hMSH2, either alone or in complex strand breaks. The initial recognition of cisplatin adducts by 
with other mismatch-recognition proteins, recognizes structural mismatch-repair proteins could also provide a signal for apoptotic cell 
distortions induced in DNA by cisplatin DNA adducts. This initial death by some other direct or indirect pathway. Another non-mutually 
binding provides a signal for the recruitment of other mismatch-repair exclusive model, repair shielding, proposes that hMSH2 and possibly 
proteins, including hMLH1 and hPMS1. Misdirected repair attempts its partner proteins shield the cisplatin adduct from DNA-repair 
at or near sites of cisplatin damage could lead to G2 arrest and the enzymes (see text). 
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that triggers cell death. In principle, the involvement of 
other mismatch-repair partner proteins would not be 
required for this mechanism to be operative. Future 
experiments will be directed at determining whether 
hMSH2, either alone or in combination with partner 
proteins, shields cisplatin adducts from repair. 
The two mechanisms outlined above could both be active in 
the organ-specific cytotoxicity of cisplatin. One complication 
with both models, however, is the possibility that HMG box 
proteins, which are abundant in the cell, may interfere with 
the ability of hMSH2 to gain access to the cisplatin adducts. 
The most likely HMG protein to interfere with hMSH2 
binding is hUBF, which binds to cisplatin adducts three to 
four orders of magnitude more tightly than other known 
HMG proteins [19]. We note, however, that hUBF is 
localized in the nucleolus [45], whereas hMSH2 is likely to 
be more generally distributed in the nucleus [46]. It is thus 
not necessarily the case that hUBF would compete with 
hMSH2 for cisplatin adducts in nuclear DNA. 
Finally, there is a growing body of evidence implicating the 
mismatch-repair machinery as a modulator of the cytotoxic 
response of cells to cisplatin. Evidence to date comes from 
the analysis of cisplatin-resistant human cell lines. Some 
tumor cell lines selected for resistance to cisplatin following 
exposure to the drug have been found to contain defects in 
mismatch-repair genes [47]. This phenotype appears to be 
common in other cisplatin-resistant lines, since it has also 
been found that such selection can result in cells that are 
deficient in G-T mismatch binding activity [48]. Also of 
possible relevance is the recent observation that a mis- 
match repair deficient cell line lacks the ability to arrest 
at the G2 checkpoint upon exposure to the base analog 
h-thioguanine. This observation led to the proposal that 
mismatch repair may be involved, either directly or 
indirectly, in triggering G’Z arrest [49]. Interestingly, 
cisplatin-induced G2 arrest prior to apoptosis has been 
observed in numerous cell lines [5,50-531. Mismatch repair 
could thus contribute to cisplatin cytotoxicity through the 
provision of either a direct or indirect signal for G2 arrest. 
All of the results detailed above predict that the 
inactivation of the mismatch-repair pathway would lead to 
tumors that are relatively refractory to treatment by 
cisplatin. Such observations may have profound clinical 
importance in determining optimum treatment regimens 
for cancer patients. 
Significance 
Chemotherapy for human cancer is clinically a far from 
ideal option because few cytotoxic drugs show an 
adequate selectivity for tumor cells, while sparing 
normal tissues. One notable exception is the treatment 
of testicular cancer which, according to recent 
estimates, is 93 % curable by a combination of surgery 
followed by chemotherapy with a regimen involving 
cisplatin as the principal cytotoxic agent [541. Several 
models have been advanced to explain the therapeutic 
efficacy of cisplatin, including the possibility that HMG 
box proteins, which bind to cisplatin adducts, might 
shield DNA lesions from repair. In the present work we 
have identified hMSH2 as a novel platinum-adduct- 
binding protein, and find that it binds selectively to the 
adducts of platinum-based drugs that show clinical 
efficacy or potential. 
The significance of the work is threefold. First, hMSH2 
is highly expressed in testis and ovary, the two tissues in 
which tumors are best treated by cisplatin. These 
observations suggest that hMSH2 may contribute to the 
organotropism of the drug. Second, our demonstration 
of an interaction between hMSH2 and cisplatin DNA 
adducts in vitro complements a growing body of 
literature correlating mismatch-repair activity with both 
cisplatin and methylating-agent cytotoxicity. Together, 
these observations are consistent with a model whereby 
mismatch repair actively enhances the toxicity of DNA 
lesions. Moreover, because mismatch-repair deficiency 
correlates with resistance to alkylating agents, our 
results may provide insight into a heretofore undis- 
covered mechanism by which tumor cells may acquire 
resistance to cisplatin. Finally, the demonstration that 
hMSH2 binds to DNA lesions other than single-base 
mismatches and insertion/deletion mispairs may indicate 
that the range of substrates for the mismatch-repair 
system is broader than previously imagined, and that 
mismatch recognition proteins may have multiple roles. 
Materials and methods 
Overexpression and purification of hMSH2 
Overexpression and purification of hMSH2 was by a modification of 
the procedures described by Fishel et al. [24]. A significant increase in 
the overexpression of hMSH2 was achieved by insertion of the gene 
into a baculovirus vector followed by infection of Sf9 insect cells. The 
protein coding sequence was modified with six histidine residues on 
the amino terminus. In a typical preparation, 250 ml of Sf9 insect cells 
were infected at a multiplicity of infection of -10 with baculovirus 
containing the hMSH2 gene under the control of the polyhedron 
promoter. All manipulations of cells were performed at 4 “C. After 72 h, 
the cells were harvested and washed once with phosphate-buffered 
saline and resuspended in lysis buffer containing 50 mM potassium 
phosphate (pH 7.5), 300 mM NaCI, 10 % glycerol (buffer A) plus 1 mM 
EDTA, 1 mM PMSF and 0.8 f.r,g ml-’ each of the protease inhibitors 
pepstatin A and leupeptin. The cells were lysed by a single freeze/thaw 
followed by Dounce homogenization. The lysate was then cleared by 
centrifugation at 100 000 x g and the supernate poured into a well 
rinsed beaker. Ammonium sulfate (45 a/o v/v) was added while stirring 
at 4 “C over a 30 min period and the mixture allowed to stir for an 
additional 30 min. The precipitate was harvested by centrifugation and 
resuspended in 4 ml buffer A plus 1 mM PMSF and 0.8 bg ml-’ each 
of pepstatin A and leupeptin. The protein was diluted to a conductivity 
equivalent to 0.5 M NaCI, applied to a 1 ml Ni-Chelex column at 0.05 
ml min-’ and washed with 10 column volumes of buffer A plus 
protease inhibitors. The bound proteins were eluted with 10 column 
volumes of buffer A plus 25 mM imidazole followed by a linear gradient 
between 25 mM and 250 mM imidazole. hMSH2 eluted between 
80 mM and 100 mM imidazole and was collected into tubes containing 
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100 pg ml-’ BSA. Peak fractions were dialyzed into 50 mM potassium 
phosphate (pH 7.5), 50 mM NaCI, 20 % glycerol, 0.1 mM EDTA, 
1 .O mM dithiothreitol, aliquotted, quick frozen in dry ice/ethanol and 
stored at -80°C. hMSH2-dependent mispair binding activity was 
stable for at least three months. The protein was generally found to be 
greater than 99 % homogeneous as judged by SDS-PAGE following 
silver staining for protein. However, occasionally the protein was less 
homogeneous and a second Heparin-Sepharose chromatography step 
was performed similar to that described by Fishel et a/. (241. 
Preparation of platinum-modified DNA probes 
cis-DDP, trans-DDP, [Pt(en)Cl,] and [Pt(dien)CIlCI were prepared as 
described [55-571. Restriction enzyme digestion of pSTR3 with C/al 
and EcoRV yielded 162-bp and 4205-bp restriction fragments. 
Platination reactions of the restriction fragments were carried out in 
3 mM NaCI, 1 mM NazHPO, (pH 7.4) with 100 pg ml-’ DNA and 
appropriate platinum compound:DNA molar ratios by incubating at 
37 “C for 16 h. Unreacted platinum compound was removed by 
dialysis (24 h) against 10 mM Tris-HCI (pH 8.0) 1 mM EDTA (TE). 
Levels of platinum modification were determined by flameless atomic 
absorption spectroscopy on a Varian AA1 475 instrument equipped 
with a GTA95 graphite furnace. The rb value determined for DNA 
modified with [Pt(dien)CIlCI was approximate. DNA probes of 162-bp 
were radiolabeled with [a-32P]dCTP (6000 Ci mmol-i, New England 
Nuclear), purified from the 4205-bp restriction fragment on native 5 % 
polyacrylamide gels, and resuspended in TE to 5000-l 0 000 counts 
per minute (cpm) per (~1. 
A lOO-bp DNA probe containing a single, centrally located cis- 
[Pt(NH,),(d(GpG)-N7(1),N7(2))] intrastrand crosslink (referred to 
above as 1,2-d(GpG)) and the analogous unmodified control were 
constructed as previously described [8], with minor modifications. All 
six deoxyoligonucleotides used in the construction were purified by 
polyacrylamide gel electrophoresis. The central 20-base oligo- 
nucleotide containing the cis-[Pt(NH,),(d(GpG)-N7(1),N7(2))1 
crosslink was resolved from unreacted DNA on a 7 M urea, 20 % 
polyacrylamide gel. Following 5’-phosphorylation with ATP of the 
appropriate oligonucleotides and subsequent annealing of 
complementary strands, ligations were conducted for 12 h at 16 “C. 
Full length probe was purified by electrophoresis from unligated 
material on a 7 M urea, 8 % polyacrylamide gel. Following reannealing 
the 1 00-bp duplex DNA was purified from single-stranded DNA by 
electrophoresis on a native 8 % polyacrylamide gel. Duplex DNA was 
eluted in 1 x TE, ethanol precipitated, air dried and resuspended in 1 x 
TE. Probes were radiolabeled with [(cY-~~PIATP (6000 Ci mmol-t, New 
England Nuclear), passed over a Sephadex G-50 Quick Spin column, 
and stored at -20 “C. 
Binding assays 
Binding assays typically contained radiolabeled 162-bp DNA probes 
(present at 100-200 pM, 5000-l 0 000 cpm) either unmodified or 
modified with platinum compounds, and purified hMSH2 present at 
O-500 nM. Binding reactions were carried out in 15 pl reactions 
containing 25 mM potassium phosphate (pH 7.5), 25 mM NaCI, 
0.5 mM dithiothreitol, 0.05 mM EDTA, 50 ug ml-’ BSA, 5 % glycerol, 
and 50 ng of nonspecific chicken erythrocyte competitor DNA. 
Binding was performed at 35 “C for 10 min. Samples were then 
loaded onto 4 % (29:l; acrylamide:bis) native polyacrylamide gels 
containing 1 x TBE (90 mM Tris (pH 8.0), 2.0 mM EDTA, 90 mM boric 
acid) and 5 % glycerol, and separated by electrophoresis at 4 “C in 
lx TBE at 25 mA for 2 h. Binding assays with lOO-bp probes 
(100 pM, 8000 cpm) were similarly conducted except that 10 ng of 
nonspecific chicken erythrocyte competitor DNA was present in the 
reactions. Amounts of bound and unbound radiolabeled probe were 
determined by quantitative analysis of dried gels using a Molecular 
Dynamics Phosphorlmager. The K,(, n) was determined by a 
nonlinear least squares fitting of the bin&n9 data to the standard Hill 
equation 1581. 
Competition assays 
Competition assays were carried out by titrating increasing amounts of 
unlabeled competitor DNA into binding reactions that contained 
constant amounts of both hMSH2 (present at 130 nM) and 32P-labeled, 
162-bp, cisplatin-modified (rb = 0.018) DNA probe (present at 150 PM). 
Unlabeled competitor was pBR322 that was either unmodified or 
modified with cisplatin (rr, = 0.043). 
Western blot analysis 
Nuclear extracts from HeLa cells were prepared as described [59]. Pre 
prepared protein extracts from adult human tissues were obtained from 
Clontech. For Western blot analysis of hMSH2,400 pg of protein from 
human tissues, 75pg of protein from HeLa nuclear extract, and 10 ng of 
purified hMSH2 were resolved on an 8 % SDS-polyacrylamide gel and 
electroblotted to nitrocellulose. For Western blot analysis of a-tubulin, 
100 pg of protein from human tissues and 75 pg of nuclear HeLa extract 
were used. The blots were incubated with a primary mouse monoclonal 
antibody either to hMSH2 (Oncogene Sciences) or to a-tubulin 
(Oncogene Sciences) followed by incubation with a horseradish 
peroxidase-labeled secondary antibody (Santa Cruz Biotechnology, Inc.). 
Antigen-specific signals were visualized using enhanced chemi- 
luminescence (Amersham) according to the manufacturer’s recom- 
mendations. Autoradiograms of Western blots were scanned using a 
Hewlett-Packard Scanjet Ilp and scanned images were analyzed using 
the NIH Image 1.6 program. Relative intensities of hMSH2 signal were 
determined after normalization to that for a-tubulin. 
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